Trials / Unknown
UnknownNCT03374293
Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer
Phase II Study of Radiation Therapy With Anti-PD-1 Antibody in Treating Patients With Unresectable Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Shixiu Wu · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody in patients with pancreatic cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiation | RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . |
| DRUG | Anti-PD-1 Antibody | Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes. |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2017-12-15
- Last updated
- 2021-02-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03374293. Inclusion in this directory is not an endorsement.